Viking Therapeutics Inc (VKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has a cash flow conversion efficiency ratio of -0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-85.29 Million) by net assets ($639.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Viking Therapeutics Inc (VKTX) balance sheet quality index to measure how much of total assets are equity-financed.
Viking Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Viking Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VKTX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Viking Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viking Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nien Made Enterprise Co Ltd
TW:8464
|
0.048x |
|
Highwoods Properties Inc
NYSE:HIW
|
0.024x |
|
MERCARI INC. UNSP.ADR/1/2
F:6TP0
|
-0.048x |
|
BW LPG Ltd
OL:BWLPG
|
0.310x |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
0.042x |
|
Jb Financial
KO:175330
|
-0.122x |
|
Taihan Electric Wire Co Ltd
KO:001440
|
-0.133x |
|
Mangalore Refinery and Petrochemicals Limited
NSE:MRPL
|
0.325x |
Annual Cash Flow Conversion Efficiency for Viking Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Viking Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see VKTX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $639.06 Million | $-87.79 Million | -0.137x | -37.75% |
| 2024-12-31 | $880.28 Million | $-87.79 Million | -0.100x | +52.64% |
| 2023-12-31 | $348.42 Million | $-73.38 Million | -0.211x | +36.76% |
| 2022-12-31 | $145.32 Million | $-48.40 Million | -0.333x | -41.29% |
| 2021-12-31 | $201.88 Million | $-47.59 Million | -0.236x | -164.47% |
| 2020-12-31 | $244.34 Million | $-21.78 Million | -0.089x | +0.22% |
| 2019-12-31 | $277.12 Million | $-24.75 Million | -0.089x | -41.80% |
| 2018-12-31 | $297.75 Million | $-18.75 Million | -0.063x | +94.25% |
| 2017-12-31 | $13.46 Million | $-14.76 Million | -1.096x | +20.38% |
| 2016-12-31 | $8.04 Million | $-11.07 Million | -1.377x | -37.55% |
| 2015-12-31 | $8.72 Million | $-8.73 Million | -1.001x | -1491.52% |
| 2014-12-31 | $-22.13 Million | $-1.59 Million | 0.072x | -76.96% |
| 2013-12-31 | $-250.60K | $-78.23K | 0.312x | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more